Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects

NCT02573155 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

134

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma (Part 1)
COPD (Part 2)

Interventions

DRUG: Dose 1, AZD8871 50 μg (Part 1)
DRUG: Dose 2, AZD8871 100 μg (Part 1)
DRUG: Dose 3, AZD8871 300 μg (Part 1)
DRUG: Dose 4, AZD8871 600 µg (Part 1)
DRUG: Dose 5, AZD8871 1200 µg (Part 1)
DRUG: Dose 6, AZD8871 1800 μg (Part 1)
DRUG: Placebo, AZD8871 placebo (Part 1)
DRUG: Treatment A, AZD8871 dose A (Part 2)
DRUG: Treatment B, AZD8871 dose B (Part 2)
DRUG: Treatment C, Indacaterol 150 μg (Part 2)
DRUG: Treatment D, Tiotropium 18 μg (Part 2)

Sponsor

AstraZeneca